A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer

Trial Profile

A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Mar 2017 Planned End Date changed from 1 Jan 2019 to 1 Oct 2021.
    • 15 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top